Wells Fargo & Company Lyell Immunopharma, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 70,607 shares of LYEL stock, worth $98,143. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,607
Previous 61,243
15.29%
Holding current value
$98,143
Previous $136,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LYEL
# of Institutions
123Shares Held
145MCall Options Held
2.6KPut Options Held
7.5K-
Mwg Management Ltd. Washington, DC20.2MShares$28 Million31.93% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$21 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$21 Million16.63% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$18.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$18.6 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $344M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...